FY2024 EPS Estimates for Ironwood Pharmaceuticals, Inc. Cut by Analyst (NASDAQ:IRWD)

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Analysts at Zacks Research cut their FY2024 earnings estimates for shares of Ironwood Pharmaceuticals in a research report issued on Tuesday, September 10th. Zacks Research analyst R. Department now anticipates that the biotechnology company will post earnings per share of $0.14 for the year, down from their prior estimate of $0.15. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.28 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q4 2024 earnings at $0.08 EPS, Q2 2025 earnings at $0.12 EPS, Q3 2025 earnings at $0.07 EPS, Q4 2025 earnings at $0.07 EPS, FY2025 earnings at $0.32 EPS, Q1 2026 earnings at $0.10 EPS and Q2 2026 earnings at $0.14 EPS.

A number of other analysts have also issued reports on IRWD. Craig Hallum lowered their price target on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. Capital One Financial lowered shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $12.00 to $4.00 in a report on Thursday, August 8th. Wells Fargo & Company lowered their price target on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, August 9th. StockNews.com upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, July 16th. Finally, Leerink Partnrs upgraded Ironwood Pharmaceuticals to a “hold” rating in a report on Monday. Three analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $13.57.

Ironwood Pharmaceuticals Stock Up 2.5 %

IRWD opened at $4.08 on Wednesday. Ironwood Pharmaceuticals has a twelve month low of $3.79 and a twelve month high of $15.70. The company has a market cap of $651.74 million, a PE ratio of -0.60 and a beta of 0.49. The company has a 50-day moving average price of $5.65 and a 200 day moving average price of $6.99.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Stonepine Capital Management LLC purchased a new position in Ironwood Pharmaceuticals during the 2nd quarter worth $313,000. Algert Global LLC purchased a new position in shares of Ironwood Pharmaceuticals in the 2nd quarter valued at approximately $93,000. Dark Forest Capital Management LP raised its stake in shares of Ironwood Pharmaceuticals by 16.5% during the second quarter. Dark Forest Capital Management LP now owns 60,386 shares of the biotechnology company’s stock worth $394,000 after purchasing an additional 8,557 shares during the last quarter. AQR Capital Management LLC grew its position in Ironwood Pharmaceuticals by 45.7% in the 2nd quarter. AQR Capital Management LLC now owns 684,578 shares of the biotechnology company’s stock valued at $4,463,000 after buying an additional 214,836 shares during the last quarter. Finally, Armistice Capital LLC increased its stake in Ironwood Pharmaceuticals by 44.4% in the 2nd quarter. Armistice Capital LLC now owns 7,800,000 shares of the biotechnology company’s stock valued at $50,856,000 after buying an additional 2,400,000 shares during the period.

Insiders Place Their Bets

In other Ironwood Pharmaceuticals news, insider Minardo John sold 9,910 shares of the stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $4.27, for a total value of $42,315.70. Following the sale, the insider now owns 284,661 shares of the company’s stock, valued at approximately $1,215,502.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 12.90% of the stock is currently owned by insiders.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.